NGeneBio Co

NGeneBio Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 155.51 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 100.33 % — a change of 55.00% (higher).

FCF Conversion

155.51 %

YoY

55.00%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of NGeneBio Co is 2025 155.51 % . FCF Conversion Rate (FCF/EBITDA) of NGeneBio Co was 2024 100.33 % . It decreases by 55.00% higher compared to the previous year.

The NGeneBio Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
178.80 KRW
Jan 1, 2019
124.01 KRW
Jan 1, 2020
72.46 KRW
Jan 1, 2021
128.61 KRW
Jan 1, 2022
92.43 KRW
Jan 1, 2023
78.28 KRW
Jan 1, 2024
100.33 KRW
Jan 1, 2025
155.51 KRW
The NGeneBio Co FCF Conversion history
YEARFCF ConversionYoY
155.51 %+55.00%
100.33 %+28.18%
78.28 %-15.32%
92.43 %-28.13%
128.61 %+77.48%
72.46 %-41.57%
124.01 %-30.64%
178.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

FCF Conversion Rate (FCF/EBITDA) of NGeneBio Co is 155.51 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of NGeneBio Co changed from 100.33 % to 155.51 %, representing a 55.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NGeneBio Co

All Key Metrics — NGeneBio Co